Proximagen Limited

Benevolentai Cambridge Limited

Proximagen Group Limited

Kathryn Oliver

Edward Savory

Michael Higginbottom

Viet-Anh Anne Horgan

Iain Simpson

Lee Patient

Andrew Graham Cole

Alison Stewart

Allison Carley

Giles Brown

Giles Albert Brown

Anne Viet-Anh Horgan

The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

Compounds I

The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R, X, Y and Rare as defined in the claims.

CXCR4 receptor antagonists

4,5,6,7-tetrahyroimidazo[4,5-c]pyridine compounds

Disclosed are compounds that are antagonists of the CXCR4 receptor.

Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds

The present invention relates to a method for the treatment or prevention of inflammation, an inflammatory disease, an immune or an autoimmune disorder, which comprises administering to a mammal in need of such treatment an effective amount of a compound compound of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity.

Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds

4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds

Growing community of inventors

Cambridge, United Kingdom

Kathryn Oliver